Takeda Pharmaceutical Company (TAK.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec18

Positive Zasocitinib Clinical Trial Data from Takeda Catalyzes New Era in Psoriasis Treatment

08:02

Nov7

Takeda Publishes New Data on Mezagitamab for IgA Nephropathy

16:01

Oct30

Takeda Pharmaceutical Company released FY2026 Semi-Annual Earnings on October 30 After-Market EST, actual revenue USD 15.13 B (forecast USD 15.48 B), actual EPS USD 0.2401

23:00

Takeda Pharmaceutical Company released FY2026 Q2 earnings on October 30, 2025, after-market EST: Actual Revenue USD 7.487 B (Forecast USD 7.97 B), Actual EPS USD -0.0251

23:00

Takeda Pharmaceutical Sees 40% Drop in Net Profit in First Half of 2023

09:21

Oct23

Takeda Pharmaceutical Company to Release FY2026 Q2 Earnings on October 30 After-Market EST, Forecast Revenue USD 7.757 B

00:08